文献速递胃肠动力与功能性疾病

大麻使用对胃轻瘫的影响:41,374例胃轻瘫患者的倾向性匹配分析

The Impact of Cannabis Use in Gastroparesis: A Propensity-Matched Analysis of 41,374 Gastroparesis Patients.
PubMed 文献 · Am J Gastroenterol · 2025-04-08

基于TriNetX网络的队列研究,对41,374例胃轻瘫患者进行1:1倾向性匹配,比较大麻使用者与非使用者。大麻使用与急诊就诊(aOR=1.73)和住院(aOR=1.44)增加相关,但内镜使用减少(aOR=0.93)。作者认为大麻使用似乎增加医疗资源利用,需仔细评估风险获益。

要点

  • 大麻使用与胃轻瘫患者急诊就诊增加相关(aOR=1.73,95%CI 1.66-1.80)。
  • 大麻使用与胃轻瘫患者住院增加相关(aOR=1.44,95%CI 1.39-1.50)。
  • 大麻使用与食管胃十二指肠镜使用减少相关(aOR=0.93,95%CI 0.88-0.98)。

核心结论

  • 胃轻瘫患者中大麻使用似乎增加医疗资源利用。
  • 作者认为需仔细评估大麻用于胃轻瘫管理的风险与获益。
  • 作者认为需前瞻性研究评估大麻素在该背景下的疗效与安全性。

研究设计与样本

  • 使用TriNetX研究网络的队列研究,纳入美国成人(≥18岁)胃轻瘫患者。
  • 采用1:1倾向性评分匹配,匹配人口学、体重指数、合并症、实验室参数和治疗。

主要发现

  • 共41,374例胃轻瘫患者,大麻使用者(n=20,687)与非使用者(n=20,687)进行倾向性匹配。
  • 大麻使用者更年轻,糖尿病、情绪/焦虑障碍、血红蛋白A1c升高和阿片类药物使用比例更高(P<0.001)。
  • 大麻使用与急诊就诊增加相关(aOR=1.73,95%CI 1.66-1.80)。
  • 大麻使用与住院增加相关(aOR=1.44,95%CI 1.39-1.50)。
  • 大麻使用与食管胃十二指肠镜使用减少相关(aOR=0.93,95%CI 0.88-0.98)。

关键数值与推荐

  • 主要结局包括急诊就诊、住院和食管胃十二指肠镜率。
  • 大麻使用与急诊就诊增加相关(aOR=1.73,95%CI 1.66-1.80)。
  • 大麻使用与住院增加相关(aOR=1.44,95%CI 1.39-1.50)。
  • 大麻使用与食管胃十二指肠镜使用减少相关(aOR=0.93,95%CI 0.88-0.98)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cannabinoids are being explored as potential treatments for gastroparesis due to their anti-emetic, gastric motility modulation, appetite stimulation, and analgesic properties coupled with their increasing use due to legalization in many states. Although these theoretical benefits are promising, clinical evidence remains limited. This study aimed to evaluate the effects of cannabis use on clinical outcomes and healthcare utilization in patients with gastroparesis using large-scale real-world data. METHODS: We conducted a cohort study using the TriNetX research network to identify US adults (≥18 years) with gastroparesis. From an initial cohort of 119 million individuals patients were stratified into cannabis users and non-users (controls). Propensity score matching (1:1) accounted for demographics, body mass index, comorbidities, laboratory parameters, and treatments. Primary outcomes included emergency department visits, hospitalizations, and esophagogastroduodenoscopy rates. RESULTS: Among 41,374 patients with gastroparesis, cannabis users (n = 20,687) and non-users (n = 20,687) were propensity-matched. Cannabis users were younger with higher rates of diabetes, mood/anxiety disorders, elevated hemoglobin A1c, and opioid use ( P < 0.001). Cannabis use was associated with increased emergency department visits (adjusted odds ratio [aOR] = 1.73, 95% confidence interval [CI]: 1.66-1.80) and hospitalizations (aOR = 1.44, 95% CI: 1.39-1.50) but reduced esophagogastroduodenoscopy utilization (aOR = 0.93, 95% CI: 0.88-0.98). DISCUSSION: Cannabis use in patients with gastroparesis seems to increase healthcare utilization. These findings underscore the need to carefully assess the risks and benefits of cannabis in gastroparesis management. Prospective studies are essential to evaluate cannabinoids' efficacy and safety in this context.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kilani Y, Gonzalez Mosquera DA, Puelo PC, et al. The Impact of Cannabis Use in Gastroparesis: A Propensity-Matched Analysis of 41,374 Gastroparesis Patients. Am J Gastroenterol. 2025. PMID: 40197432. doi:10.14309/ajg.0000000000003479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。